Summit Therapeutics Plc Stock Alpha and Beta Analysis

SMMT Stock  USD 22.36  0.72  3.33%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Summit Therapeutics PLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Summit Therapeutics over a specified time horizon. Remember, high Summit Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Summit Therapeutics' market risk premium analysis include:
Beta
2.01
Alpha
0.14
Risk
4.61
Sharpe Ratio
0.0641
Expected Return
0.3
Please note that although Summit Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Summit Therapeutics did 0.14  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Summit Therapeutics PLC stock's relative risk over its benchmark. Summit Therapeutics PLC has a beta of 2.01  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Summit Therapeutics will likely underperform. At this time, Summit Therapeutics' Book Value Per Share is comparatively stable compared to the past year. Tangible Asset Value is likely to gain to about 49.4 M in 2025, whereas Price Book Value Ratio is likely to drop 22.74 in 2025.

Enterprise Value

1.56 Billion

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Summit Therapeutics Backtesting, Summit Therapeutics Valuation, Summit Therapeutics Correlation, Summit Therapeutics Hype Analysis, Summit Therapeutics Volatility, Summit Therapeutics History and analyze Summit Therapeutics Performance.

Summit Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Summit Therapeutics market risk premium is the additional return an investor will receive from holding Summit Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Summit Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Summit Therapeutics' performance over market.
α0.14   β2.01

Summit Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Summit Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Summit Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Summit Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Summit Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Summit Therapeutics shares will generate the highest return on investment. By understating and applying Summit Therapeutics stock market price indicators, traders can identify Summit Therapeutics position entry and exit signals to maximize returns.

Summit Therapeutics Return and Market Media

The median price of Summit Therapeutics for the period between Sat, Nov 2, 2024 and Fri, Jan 31, 2025 is 18.77 with a coefficient of variation of 9.43. The daily time series for the period is distributed with a sample standard deviation of 1.83, arithmetic mean of 19.42, and mean deviation of 1.45. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
11/21/2024
2
Is Summit Therapeutics Inc. the Best Performing Biotech Stock in 2024
12/23/2024
3
Acquisition by Booth Robert F. of 6855 shares of Summit Therapeutics at 18.35 subject to Rule 16b-3
01/02/2025
4
Summit Therapeutics Inc to Present at J.P. Morgan Healthcare Conference
01/07/2025
5
Acquisition by Bhaskar Anand of 75000 shares of Summit Therapeutics at 17.85 subject to Rule 16b-3
01/10/2025
6
Why Summit Therapeutics Rocketed 584 percent in 2024
01/15/2025
7
Why Summit Therapeutics Stock Is Jumping Today
01/21/2025
8
Acquisition by Xia Yu of 200000 shares of Summit Therapeutics at 2.64 subject to Rule 16b-3
01/28/2025
9
Up More Than 500 percent in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock - sharewise
01/30/2025

About Summit Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Summit or other stocks. Alpha measures the amount that position in Summit Therapeutics PLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2020 2024 2025 (projected)
Payables Turnover7.080.691.17
Days Of Inventory On Hand43.8K39.4K41.4K

Summit Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Summit Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Summit Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Summit Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Summit Therapeutics. Please utilize our Beneish M Score to check the likelihood of Summit Therapeutics' management manipulating its earnings.
14th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Build Portfolio with Summit Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.